News Releases

Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
Menlo Park, CA, February 3, 2011 — Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors. Dr. Chaudhuri most recently served as President of Valeant Pharmaceuticals International and previously was President and Chief Executive Officer of Dow Pharmaceutical Services, Inc. Mr. Greenwood is Executive Vice President and Chief Financial Officer of Geron Corporation.

Corium International, Inc. HJonored with 2010 Edison Award
Menlo Park, CA, May 2010 — Corium International, Inc. announced that it was honored with the silver medal Edison Award for its MicroJet Transdermal Drug Delivery System. The prize was awarded in the Science and Medical category for “Best New Products — Game Changers” in New York City on April 29, 2010. The award was presented by the Chair of the Best New Products group to Corium and two other recipients for products whose innovative approach to technology can change the way medicine is practiced…

Corium International, Inc. Honored as P&G’s External Business Partner of the Year
Menlo Park, CA, November 16, 2009 — Corium International, Inc. announced that it was honored with the External Business Partner of the Year award by The Procter & Gamble Company at its Global Business Development Awards Dinner on November 5, 2009. The annual event acknowledges the successful external “partners who have significantly contributed to P&G’s business either through enabling networks or partnerships to create new and improved consumer products and services,” according to Jeffrey D. Weedman, Vice President of Global Business Development for P&G…

Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
Menlo Park, CA, November 27, 2007 — Corium International, Inc., a privately-held transdermal drug delivery company, today announced the appointment of Phyllis Gardner, M.D. and Daniel G. Welch to the Board of Directors. Dr. Gardner, an adjunct partner at Essex Woodlands Health Ventures, is a Professor of Medicine at Stanford University and widely published in the fields of cell biology and pharmacology. In addition…

Corium International, Inc., Announces $40 Million Financing lead by Essex Woodlands Health Ventures
MenloPark, CA
Menlo Park, CA, September 26, 2007 — Corium International, Inc., a privately-held transdermal drug delivery company, today announced that it has completed a $25.1 million Series C financing led by Essex Woodlands Health Ventures. Quantum Technology Partners, Aphelion Capital and a strategic investor also participated in the round. In connection with the financing, StrataGent Life Sciences, Inc., an Essex Woodlands Health Ventures portfolio company focused on needlefree delivery of drugs, will merge into Corium. Corium and Essex Woodlands Health Ventures have also set terms for a $15.2 million Series D financing to occur within 24 months, subject to certain conditions. Seven Hills Partners LLC acted as Corium’s exclusive financial advisor and placement agent in these transactions…